The Expora Platform™

Expora has developed a suite of technologies and processes to address critical roadblocks to BEV development towards realization of their transformative potential

Platform

Leaders in Bacterial Extracellular Vesicle Manufacturing and Design

Industry leading technologies and expertise enable Expora to manufacture and design bacterial extracellular vesicles (BEVs) for numerous potential applications

  • E. coli, Lactobacillus, and Bifidobacterium producer cells as well as novel strains

  • BEV-specific analytics to track CQAs

  • Process optimized for batch-to-batch and sample consistency

Platform

Leaders in Bacterial Extracellular Vesicle Manufacturing and Design

Industry leading technologies and expertise enable Expora to manufacture and design bacterial extracellular vesicles (BEVs) for numerous potential applications

  • E. coli, Lactobacillus, and Bifidobacterium producer cells as well as novel strains

  • BEV-specific analytics to track CQAs

  • Process optimized for batch-to-batch and sample consistency

Platform

Leaders in Bacterial Extracellular Vesicle Manufacturing and Design

Industry leading technologies and expertise enable Expora to manufacture and design bacterial extracellular vesicles (BEVs) for numerous potential applications

  • E. coli, Lactobacillus, and Bifidobacterium producer cells as well as novel strains

  • BEV-specific analytics to track CQAs

  • Process optimized for batch-to-batch and sample consistency

3x

3x

3x

Potency

Potency

Potency

60x

60x

60x

Yield

Yield

Yield

10-100x

10-100x

10-100x

Lower Cost

Lower Cost

Lower Cost

BEVstudio: Design & Discover New Compositions

Expora has industry-leading patent-pending engineering technology and deep expertise to modify BEV payloads for specific applications including tissue-specific targeting and therapeutic loading (small molecule, protein, peptides, RNA)

The Expora Platform™ applies the power of synthetic biology by genetically programming non-inflammatory bacteria originally isolated from the human body for production of gut-targeted, multi-specific EV therapeutics. A product of over a decade in development and $10M of federally-funded research, our technology derisks multiple aspects of EV development.

BEVfactory: Scalable, Consistent Manufacturing

Historically low EV/BEV production yields have mandated production scaleup far earlier in development than typical, introducing major risk and costs. Expora's patent-pending cell lines and processes bring costs and scaleup needs on par with conventional biologics, enabling de-risked and accelerated development, and sufficiently low cost of goods to access consumer markets.

Partner With Us to Advance the Future of Extracellular Vesicle Therapeutics

We are seeking collaborators, funders, scientific and strategic partners who share our commitment to advancing the future of exosome therapeutics.

Partner With Us to Advance the Future of Extracellular Vesicle Therapeutics

We are seeking collaborators, funders, scientific and strategic partners who share our commitment to advancing the future of exosome therapeutics.

Partner With Us to Advance the Future of Extracellular Vesicle Therapeutics

We are seeking collaborators, funders, scientific and strategic partners who share our commitment to advancing the future of exosome therapeutics.